Evidence map›Paper›PMID 40412613›Full record

ArticleThe journal of allergy and clinical immunology. In practice2025

Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study.

Matthew S Krantz, Chantal Lemoine, Li Zhou, Andrew J King, Daniela Kroshinsky, Elizabeth J Phillips, Kimberly G Blumenthal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew S KrantzDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tenn; Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Chantal LemoineDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Li ZhouHarvard Medical School, Boston, Mass; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Mass.
Andrew J KingDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Daniela KroshinskyDepartment of Dermatology, Duke University School of Medicine, Durham, NC.
Elizabeth J PhillipsCenter for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.
Kimberly G BlumenthalDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Department of Dermatology, Massachusetts General Hospital, Boston, Mass. Electronic address: kblumenthal@mgh.harvard.edu.

Funding

NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0M
Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial)U01AI184071 · NIAID · MAYO CLINIC JACKSONVILLE · PI Kimberly G. Blumenthal, DAVID A KHAN · 2024 to 2026
$9.4M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Clinical Informatics to Advance Epidemiology and Pharmacogenetics of Serious Cutaneous Adverse Drug ReactionsR01AI150295 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHOU, LI · 2019 to 2022
$2.8M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
A Translational Bioinformatics Approach for Phenotyping and Genetic Risk of Severe Cutaneous Adverse Drug ReactionsK08AI185260 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Matthew Steven Krantz · 2025 to 2026
$373k
AHRQ HHS R01 HS029319NHGRI NIH HHS R01 HG010863NIAID NIH HHS K08 AI185260NIAID NIH HHS L30 AI186122NIAID NIH HHS R01 AI150295NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIAID NIH HHS U01 AI184071NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40412613
PMCPMC12335362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.